February 23rd, 2022
Cantex licenses IP from Harvard to develop repurposed drug identified by Wyss Institute to treat inflammatory lung diseases including COVID-19
Organ Chip studies revealed azeliragon can reduce virus-associated inflammation in human lung tissue